

## Disclosures

### Personal Commercial (14)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
AstraZeneca Pharmaceuticals	Speaker's Bureau	Modest (< \$5,000)	<i>General Cardiology Heart Failure and Cardiomyopathies</i>
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology Heart Failure and Cardiomyopathies</i>
Boehringer Ingelheim Pharmaceuticals, Inc	Speaker's Bureau	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Bristol-Myers Squibb Company	Speaker's Bureau	Modest (< \$5,000)	<i>Arrhythmias and Clinical EP</i>
Bristol-Myers Squibb Company	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Other</i>
Daiichi Sankyo	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Prevention</i>
Menarini Group	Speaker's Bureau	Modest (< \$5,000)	<i>Prevention</i>
Novartis Corporation	Speaker's Bureau	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Novartis Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Pfizer Inc	Speaker's Bureau	Modest (< \$5,000)	<i>Prevention</i>
Roche diagnostics	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Roche diagnostics	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 10/16/2021

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/16/2021

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 10/16/2021

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.